Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know By: Benzinga via Benzinga April 22, 2016 at 10:52 AM EDT JPMorgan’s Anupam Rama believes data from the two phase 3 trials of fostamatinib would be positive and that Rigel ... Read More >> Related Stocks: Rigel Pharmaceuticals